Donald L. Barbeau President and Chief Scientific Officer
Donald L. Barbeau has over 45 years of experience in the health care industry, principally in the area of pharmaceutical development and intellectual property management. He is currently serving as President and Chief Scientific Officer of B&G Partners LLC (the licensor of Oncorx's intellectual property) and President of Asklepios Foundation (a not-for-profit company). Most recently he was founder and Chief Scientific Officer of two early-stage drug development companies. He was a co-founder of ProCor Pharmaceuticals, Inc. and founder of Barbeau Pharma Inc., where he was Chief Scientific Officer and served on the Board of Directors for both companies. Mr. Barbeau is the inventor of the proprietary technologies used in Oncorx's current development programs and the inventor on over 14 United States patents and multiple European patents. Earlier in his career, Mr. Barbeau conducted cardiovascular research at the University of Chicago in the Specialized Center of Research on Arteriosclerosis and the Editor-in-Chief of a medical journal covering clinical trials. Mr. Barbeau is the recipient of BS and MS degrees in Biochemistry and Biophysics, an MBA from the Illinois Institute of Technology and studied for his PhD degree in Biochemistry at the University of Chicago.
Barbara K. Barbeau Chief Regulatory Officer
Barbara K. Barbeau has over 32 years of experience in the health care industry, principally in the area of regulatory affairs, product development, mergers and acquisitions and intellectual property management. Most recently she was Senior Director of Global Regulatory Affairs for Baxter Healthcare Corporation and managed its international regulatory affairs group. During her career, Ms. Barbeau was responsible for submitting multiple dossiers and received regulatory approval from the FDA and EC for a number of commercial products including 23 Class I-III medical devices covering transfusion therapies, 30 NDAs, 36 ANDAs and 9 grandfathered pharmaceutical products. Ms. Barbeau is the recipient of a BS degree in Chemistry and studied for her PhD degree in Chemistry at the Illinois Institute of Technology in Chicago.
We would like to thank our collaborators who have provided valuable assistance, research, and/or intellectual property to our development program:
B&G Partners, LLC
University of Toledo, Center for Drug Design and Development
University of Michigan, Comprehensive Cancer Center